Defining the risk of SARS-CoV-2 variants on immune protection - Ghedin, Elodie; Krammer, Florian; Grifoni, Alba; Alter, Galit; Baric, Ralph S.; Barouch, Dan H.; Bloyet, Louis-Marie; Bonenfant, Gaston; Boon, Adrianus C. M.; Boritz, Eli A.; Bratt, Debbie L.; Bricker, Traci L.; et al. (Nature (London), 2022)
Keywords: 631/250/590; 692/699/255/2514; Allergies; Animal models; Animals; Antiviral drugs; Bioinformatics; Biological Evolution; Collaboration; Coronaviruses; COVID-19; COVID-19 Vaccines; Disease transmission; Evolution; Evolution & development; Genomes; Health risks; Human populations; Humanities and Social Sciences; Humans; Immunity; Infections; Infectious diseases; Life Sciences; Microbiology and Parasitology; multidisciplinary; Mutation; National Institute of Allergy and Infectious Diseases (U.S.); Pandemics; Pandemics - prevention & control; Peer review; Perspective; Pharmacogenomic Variants; Proteins; Public health; R&D; Reagents; Research & development; Respiratory diseases; Risk assessment; Risk communication; SARS-CoV-2 - genetics; SARS-CoV-2 - pathogenicity; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Teams; United States - epidemiology; Vaccines; Viral diseases; Virology; Virulence; Viruses; United States; United States--US; Variants of concern; SARS-CoV-2